#Israel #Caesarea #IceCure Medical #Cryoablation #Rights Offering

IceCure Medical's Rights Offering Deadline Approaching

IceCure Medical Ltd. (Nasdaq: ICCM), known for its advanced minimally invasive cryoablation technology, is reaching out to its shareholders with an important reminder. The subscription period for the company's recently announced rights offering is set to expire on July 28, 2025, at 5:00 PM Eastern Time. Interested shareholders should act swiftly to ensure they capitalize on this opportunity to further invest in the innovative field of tumor treatment.

The rights offering is part of IceCure's ongoing efforts to expand the application of its cutting-edge cryoablation technology, which utilizes freezing methods to selectively destroy tumors, offering a less invasive alternative to traditional surgical procedures. As emphasized, the rights offering allows shareholders to purchase up to an aggregate of 10 million units, each at a subscription price of $1.00 per whole unit.

Subscription Process Details

The rights offering is open to all holders of the company's ordinary shares as of the record date of July 9, 2025. Each shareholder will receive non-transferable subscription rights, granting them the opportunity to purchase units consisting of an ordinary share paired with a warrant for further investment. Specifically, each subscription right grants its holder the right to purchase approximately 0.1703 of a unit. For those who wish to acquire units, it’s paramount to understand the process of exercising these rights effectively.

For shareholders opting to exercise their subscription rights through brokers or other nominees, it is essential to communicate directly with them soon. These intermediaries may impose their deadlines, which can precede the official expiration date set by IceCure. Early engagement ensures that all necessary documentation and payments are processed in a timely manner.

Broadridge Corporate Issuer Solutions, LLC has been appointed as the subscription agent for the rights offering. Shareholders can contact Broadridge at its dedicated number for any inquiries or clarifications pertaining to the rights offering process. Additionally, anyone requiring further insight is encouraged to reach out to Maxim Group LLC, the dealer-manager for the offering, for assistance in navigating this investment opportunity.

Importance of Acting on Subscription Rights

It's important to note that if shareholders do not exercise their subscription rights before the deadline, these rights will expire without any value. Therefore, interested investors should make informed decisions based on their assessment of IceCure's business prospects and the overall investment landscape.

The company remains steadfast in its commitment to advancing cryoablation technology. Its flagship product, the ProSense® system, has gained market presence across several regions including the United States, Europe, and Asia, and continues to receive attention for its effectiveness in treating various types of tumors, including those located in the breast, kidney, lung, and bone.

Conclusion

As IceCure Medical looks toward the future, it urges all eligible shareholders to thoroughly consider their positions in relation to the rights offering. This could be a pivotal moment not only for the company but also for investors wishing to be part of a pioneering solution in cancer treatment. The deadline of July 28, 2025, is imminent, and time is of the essence for those choosing to participate in this investment opportunity.